Acetaminophen Proposals Could Hit Firms Hard Via Sales And Costs
This article was originally published in The Tan Sheet
Executive Summary
Acetaminophen product manufacturers stand to incur huge costs and reduced revenue opportunities if FDA implements a working group's recommendations to reduce hepatotoxicity risk
You may also be interested in...
U.K. Tightens Restrictions On Nonprescription Pain Reliever Sales
The U.K. Medicines and Healthcare products Regulatory Agency recommends retailers restrict sales of nonprescription pain relievers to two packs per transaction to reduce the risk of overdose - a strategy an FDA working group rejected
U.K. Tightens Restrictions On Nonprescription Pain Reliever Sales
The U.K. Medicines and Healthcare products Regulatory Agency recommends retailers restrict sales of nonprescription pain relievers to two packs per transaction to reduce the risk of overdose - a strategy an FDA working group rejected
U.K. Tightens Restrictions On Nonprescription Pain Reliever Sales
The U.K. Medicines and Healthcare products Regulatory Agency recommends retailers restrict sales of nonprescription pain relievers to two packs per transaction to reduce the risk of overdose - a strategy an FDA working group rejected